Outcomes associated with Hydroxychloroquine and Ivermectin in hospitalized patients with COVID-19: a single-center experience
Ferreira et al.,
Outcomes associated with Hydroxychloroquine and Ivermectin in hospitalized patients with COVID-19: a..,
Revista da Associação Médica Brasileira, doi:10.1590/1806-9282.20210661
Retrospective 230 hospitalized patients in Brazil showing no significant difference with ivermectin treatment. Authors note that the treatments were more likely to be offered to sicker patients. Authors indicate that they do not know when medication was started, which in some cases could have been after ICU admission or intubation. Baseline total chest CT opacities was 20% for ivermectin vs. 15% for control. Dosage is unknown.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details; substantial unadjusted
confounding by indication likely.
risk of death, 5.0% higher, RR 1.05, p = 1.00, treatment 3 of 21 (14.3%), control 11 of 81 (13.6%).
|
risk of death/intubation, 54.3% higher, RR 1.54, p = 0.37, treatment 6 of 21 (28.6%), control 15 of 81 (18.5%).
|
risk of death/intubation/ICU, 62.4% higher, RR 1.62, p = 0.27, treatment 8 of 21 (38.1%), control 19 of 81 (23.5%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Ferreira et al., 26 Nov 2021, retrospective, Brazil, peer-reviewed, 5 authors, study period 12 March, 2020 - 8 July, 2020, average treatment delay 7.0 days, dosage not specified.
Abstract: ORIGINAL ARTICLE
https://doi.org/10.1590/1806-9282.20210661
Outcomes associated with Hydroxychloroquine
and Ivermectin in hospitalized patients with
COVID-19: a single-center experience
Roberto Muniz Ferreira1,2* , Renata Wanderley Beranger1 ,
Pedro Paulo Noguères Sampaio1,2 , João Mansur Filho1 ,
Ricardo Antônio Correia Lima1,3
SUMMARY
OBJECTIVE: Hydroxychloroquine and Ivermectin are advocated as potential treatments for coronavirus disease 2019 (COVID-19) despite
the lack of supportive clinical evidence. In this study, outcomes associated with Hydroxychloroquine and/or Ivermectin were determined
in a series of patients with confirmed COVID-19 from a single institution in Brazil.
METHODS: Consecutive patients admitted between March and July 2020 were retrospectively analyzed and divided into four treatment
categories: no treatment (Group 0), Ivermectin only (Group I), Hydroxychloroquine only (Group II), and Hydroxychloroquine and Ivermectin
(Group III). Intensive care unit admission, mechanical ventilation, and death were compared between the Groups.
RESULTS: A total of 230 patients were included, with the following treatment distribution: 35.2% (0), 9.1% (I), 48.3% (II), and 7.4%
(III). Groups I, II, and III had the higher rates of Intensive care unit admission, mechanical ventilation, or death (0: 23.5% versus I: 38.1%
versus II: 37.8% versus III: 70.6%, p=0.002), and the greatest mortality was found in Group III (0 versus III: 13.6% versus 35.3%, p=0.03).
In the multivariate analysis, Hydroxychloroquine remained significantly associated with death (OR 3.3, 95%CI 1.1–9.6, p=0.03).
CONCLUSION: In a series of consecutive hospitalized patients with COVID-19, Ivermectin was not associated with improved outcomes
and Hydroxychloroquine may have resulted in a harmful effect.
KEYWORDS: Coronavirus. Hydroxychloroquine. Ivermectin. Prognosis.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit